Epigenetic silencing of MAFG is a potential prognosis biomarker in lung adenocarcinomas
Álvaro García-Guede, Carlos Rodríguez‐Antolín, Ana Arauzo-Cabrera, Rocío Moreno-Velasco, Olga Pernía, Miranda Burdiel Herencia, Lucía Acero-Riaguas, Isabel Esteban‐Rodríguez, Silvia Sacristán, Raúl Torres-Ruiz, Sandra Rodríguez, Ana Sastre-Perona, Victor M. Gonzalez, Javier de Castro, Inmaculada Ibañez de Cáceres, Olga Vera
The paper investigates MAFG's role in DNA methylation remodeling in NSCLC, finding that MAFG methylation and protein levels are prognostic biomarkers, especially in lung adenocarcinomas.
bioRxiv · May 29, 2026 · PreprintCancer Biology